154 related articles for article (PubMed ID: 10694470)
21. Over-expression of betaI tubulin in MDCK cells and incorporation of exogenous betaI tubulin into microtubules interferes with adhesion and spreading.
Lezama R; Castillo A; Ludueña RF; Meza I
Cell Motil Cytoskeleton; 2001 Nov; 50(3):147-60. PubMed ID: 11807936
[TBL] [Abstract][Full Text] [Related]
22. Multiple resistance mechanisms in Chinese hamster cells resistant to 9-hydroxyellipticine.
Larsen AK; Jacquemin-Sablon A
Cancer Res; 1989 Dec; 49(24 Pt 1):7115-9. PubMed ID: 2582453
[TBL] [Abstract][Full Text] [Related]
23. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
Ranganathan S; Dexter DW; Benetatos CA; Chapman AE; Tew KD; Hudes GR
Cancer Res; 1996 Jun; 56(11):2584-9. PubMed ID: 8653701
[TBL] [Abstract][Full Text] [Related]
24. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
Ranganathan S; McCauley RA; Dexter DW; Hudes GR
Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260
[TBL] [Abstract][Full Text] [Related]
25. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
Banerjee A
Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644
[TBL] [Abstract][Full Text] [Related]
26. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
Kelly EB; Tuszynski JA; Klobukowski M
J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
[TBL] [Abstract][Full Text] [Related]
27. Maytansine-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin.
Schibler MJ; Cabral FR
Can J Biochem Cell Biol; 1985 Jun; 63(6):503-10. PubMed ID: 4041962
[TBL] [Abstract][Full Text] [Related]
28. Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential.
Lelièvre S; Larsen AK
Cancer Res; 1994 Aug; 54(15):3993-7. PubMed ID: 8033129
[TBL] [Abstract][Full Text] [Related]
29. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.
Tsuruo T
Cancer Treat Rep; 1983 Oct; 67(10):889-94. PubMed ID: 6354436
[TBL] [Abstract][Full Text] [Related]
30. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
31. Increased sensitivity to Vinca alkaloids in cells overexpressing calmodulin by gene transfection.
Ido M; Lagacé L; Chafouleas JG
Cancer Res; 1990 Oct; 50(20):6554-8. PubMed ID: 2208115
[TBL] [Abstract][Full Text] [Related]
32. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
33. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
34. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
[TBL] [Abstract][Full Text] [Related]
35. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
[TBL] [Abstract][Full Text] [Related]
36. Divalent cation and ionic strength effects on Vinca alkaloid-induced tubulin self-association.
Lobert S; Boyd CA; Correia JJ
Biophys J; 1997 Jan; 72(1):416-27. PubMed ID: 8994628
[TBL] [Abstract][Full Text] [Related]
37. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations.
Verrills NM; Walsh BJ; Cobon GS; Hains PG; Kavallaris M
J Biol Chem; 2003 Nov; 278(46):45082-93. PubMed ID: 12949081
[TBL] [Abstract][Full Text] [Related]
38. Gene amplification-associated cytogenetic aberrations and protein changes in vincristine-resistant Chinese hamster, mouse, and human cells.
Meyers MB; Spengler BA; Chang TD; Melera PW; Biedler JL
J Cell Biol; 1985 Feb; 100(2):588-97. PubMed ID: 3968181
[TBL] [Abstract][Full Text] [Related]
39. Intracellular beta-tubulin/chaperonin containing TCP1-beta complex serves as a novel chemotherapeutic target against drug-resistant tumors.
Lin YF; Tsai WP; Liu HG; Liang PH
Cancer Res; 2009 Sep; 69(17):6879-88. PubMed ID: 19690144
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological properties of a new alpha-aminophosphonic acid derivative of vinblastine.
Pierré A; Lavielle G; Hautefaye P; Seurre G; Leonce S; Saint-Dizier D; Boutin JA; Cudennec CA
Anticancer Res; 1990; 10(1):139-44. PubMed ID: 2334119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
